The Reimbursement Landscape for Novel Diagnostics: Current Limitations.
The success of personalized medicine is dependent on the healthcare industry’s ability to overcome several clinical, economic, and logistical challenges to commercialization.
A continuum of niche, moderate, and broad reform solutions offer different levels of beneficial impact and feasibility of execution.
Niche solutions address specific issues in the short- to mid-term. Examples include establishing a set of complex analytics codes, a system of test-specific codes, and a set of economic study standards for novel diagnostics.
Moderate solutions impact multiple issues in the mid-term. Some examples involve facilitating diagnostic coverage with evidence development and/or risk-sharing payment schemes.
Broad reform solutions require significant time and resources but provide the most impact, such as the establishment of a single coverage and value assessment body for novel diagnostics.
No individual reform measure can positively impact the entire system. A multi-solution approach to the current system’s limitations can provide short-term benefits while building towards broader diagnostic reimbursement reform.